| Unique ID issued by UMIN | UMIN000056422 |
|---|---|
| Receipt number | R000064469 |
| Scientific Title | Efficacy and safety analysis of pre-co-seasonal sublingual immunotherapy for Japanese cedar pollinosis: A multicenter randomized parallel-group comparative trial |
| Date of disclosure of the study information | 2025/01/01 |
| Last modified on | 2025/06/11 09:09:51 |
Efficacy and safety analysis of pre-co-seasonal sublingual immunotherapy for Japanese cedar pollinosis
PC-SLIT for JCP
Efficacy and safety analysis of pre-co-seasonal sublingual immunotherapy for Japanese cedar pollinosis: A multicenter randomized parallel-group comparative trial
PC-SLIT for JCP
| Japan |
Japanese cedar pollinosis
| Oto-rhino-laryngology |
Others
NO
Currently, sublingual immunotherapy for Japanese cedar pollinosis, which is a curative treatment, is administered throughout the year. However, in other countries, pre-co-seasonal sublingual immunotherapy (PC-SLIT), which is administered from three months before the pollen season to during the pollen season, is mainstream, and its efficacy and safety have been demonstrated. This study aims to evaluate the efficacy and safety of PC-SLIT for Japanese cedar pollonosis.
Efficacy
Total nasal symptom score over one Week during the peak of the pollen season
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
| Medicine |
Pre-co-seasonal sublingual immunotherapy
Year-round sublingual immunotherapy
| 5 | years-old | <= |
| Not applicable |
Male and Female
1.Patients with Japanese cedar pollinosis who started sublingual immunotherapy with cedar sublingual tablets (Cedarcure) during the year 2024
2.Patients who are maintained on sublingual immunotherapy with Cedarcure 5,000 JAU tablets
3.Patients with a serum cedar-specific IgE class of 2 or higher
4.Patients who can obtain written consent from themselves to participate in the study of their own free will
5.Patients who are 5 years or older at the time of consent
6.Gender: Not specified
7.Outpatient
1.Women who are pregnant or may become pregnant
2.Patients diagnosed with cancer
3.Patients taking oral steroids (more than 10 mg/day of prednisolone for more than two consecutive weeks)
4.Patients receiving omalizumab, dupilumab, mepolizumab, benralizumab, or tezepelumab
5.Patients with severe asthma
6.Patients with a history of anaphylaxis
7.Patients with a history of hypersensitivity to adrenaline
8.Patients judged to have complications or infections that affect the heart, liver, kidneys, blood diseases, or other conditions that could impact the conduct of the study
9.Patients deemed unsuitable for study participation by the investigator
80
| 1st name | Mitsuhiro |
| Middle name | |
| Last name | Okano |
International University of Health and Welfare
Otorhinolaryngology, Head and Neck Surgery
2868686
852 Hatakeda, Narita
0476-35-5600
mokano@iuhw.ac.jp
| 1st name | Maiko |
| Middle name | |
| Last name | Maruyama |
International University of Health and Welfare
Otorhinolaryngology, Head and Neck Surgery
2868686
852 Hatakeda, Narita
0476-35-5600
maruyama-maiko-kj@iuhw.ac.jp
International University of Health and Welfare
AMED
Japanese Governmental office
International University of Health and Welfare Ethics Review Board for Clinical Research
852 Hatakeda, Narita
0476-35-5600
rinri_md@iuhw.ac.jp
NO
| 2025 | Year | 01 | Month | 01 | Day |
Unpublished
89
No longer recruiting
| 2024 | Year | 10 | Month | 10 | Day |
| 2024 | Year | 10 | Month | 10 | Day |
| 2025 | Year | 04 | Month | 01 | Day |
| 2026 | Year | 07 | Month | 31 | Day |
| 2026 | Year | 07 | Month | 31 | Day |
| 2026 | Year | 07 | Month | 31 | Day |
| 2027 | Year | 03 | Month | 31 | Day |
| 2024 | Year | 12 | Month | 10 | Day |
| 2025 | Year | 06 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064469